69.25
-0.23%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Hotgen Biotech Co
Its shares trade on Shanghai under the ticker 688068.SS. It has been listed since 30 September 2019. In the fiscal year to 31 December 2025, it reported a net loss of CN¥210.5m. At that date it held total assets of CN¥3.18bn and shareholders' equity of CN¥2.93bn.
Beijing Hotgen Biotech Co., Ltd. engages in the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The company is headquartered in Beijing, Beijing. The company went IPO on 2019-09-30. The firm's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The firm primarily conducts its businesses in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 30 Sept 2019
- Employees
- 1,179
- Website
- hotgen.com.cn ↗
Leadership
Pay as last reported
- Mr. Shukui DongIndependent DirectorCN¥82,500
- Mr. Changqing LinChairman of the Board, General Manager, since 2019CN¥8.9m
- Mr. Zhongchao XieChief Financial Officer
- Mr. Yongzhan ShiDeputy General Manager, Secretary of the Board, Director, since 2019CN¥2.5m
- Mr. Yanzhao LiDeputy General Manager, Director, since 1983
- Mr. Shaohua YuDeputy General Manager, Director, since 2019CN¥5.5m
- Ms. Xiaochi JieDeputy General Manager
- Mr. Haifeng SunDeputy General ManagerCN¥2.0m
- Mr. Wei MinDirector of Biochemiluminescent Reagent R&D Transformation Department, Director of Reagent Quality Assurance DepartmentCN¥1.7m
- Ms. Xiaoli LiuDirector, since 2022
- Mr. Shen QiDirector
- Mr. Xin ZhouDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Hotgen Biotech employs 1,179 full-time staff members globally.
- The firm develops in vitro diagnostic reagents for clinical use.
- Products address liver cancer and hepatitis diagnostic needs effectively.
Weaknesses
- The company is headquartered in Beijing, China, which limits local reach.
- Only 1,179 employees work for the listed biotech firm.
- Listing occurred on 30 September 2019, limiting recent market history.
Opportunities
- Expanding overseas markets offers growth for domestic diagnostic products.
- Public safety fields require biosafety and food safety solutions.
- Disease control sectors need emergency response diagnostic tools urgently.
Threats
- Competitors in the Life Sciences Tools sector dominate global markets.
- Regulatory changes in China may impact manufacturing operations significantly.
- Economic downturns could reduce spending on cardiovascular diagnostic instruments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.